Active pharmaceutical ingredient (API) manufacturing is essential for producing safe, effective, and high-quality medicines, directly impacting drug efficacy, safety, and regulatory compliance in the pharmaceutical industry.
Investment marks continued progress against AbbVie's $100 billion commitment to US R&D and capital investments, including manufacturing, over the next decade.
Agno Pharma acquired Actylis's Eugene, Oregon CDMO facility, formerly Cascade Chemistry, for small-molecule API development and manufacturing, thereby expanding its US footprint.
Curia has completed a $4 million upgrade to its sterile API manufacturing suites in Valladolid, Spain, to enhance product quality, safety, and regulatory compliance.
SK Pharmteco has announced a $6.1 million investment to expand its Rancho Cordova, California, facility with new lab and kilo-scale capabilities for solid-phase peptide synthesis and purification.
New state-of-the-art active pharmaceutical ingredient (API) facility in North Chicago will manufacture immunology, oncology, and neuroscience medicines.
CDMO Cambrex announced that Snapdragon Chemistry, a Cambrex company, has expanded its active pharmaceutical ingredient (API) facility in Waltham, Massachusetts
AbbVie announced a $195 million investment in its North Chicago, Illinois manufacturing plant to expand domestic active pharmaceutical ingredient (API) production in the US.
Ofichem, a European CDMO specialising in high-quality active pharmaceutical ingredients (APIs) and integrated drug development and manufacturing services, has acquired Meribel Pharma Solutions’ site in Uppsala, Sweden.
Nippon Shokubai recently announced plans to expand its GMP-compliant manufacturing capacity for nucleic acid drug active pharmaceutical ingredients (APIs) tenfold.
CDMO Suanfarma appoints Pere Mañé Godina as its new CEO, marking the beginning of a new chapter for the company, focused on industrial consolidation, sustainable innovation, and global expansion.
HAS Healthcare Advanced Synthesis (HAS) recently announced the planned acquisition of Cerbios-Pharma (Cerbios), a globally recognized manufacturer of chemical and biological APIs, including antibody-drug conjugates (ADCs).
IMCD Group, a global distribution partner and formulator of specialty chemicals and ingredients, recently announced the expansion of its Pharmaceuticals Technical Centre in Jakarta, Indonesia. This facility will serve as the hub for pharmaceutical development and innovation across Southeast Asia, Australia, and New Zealand.
Cambrex announced that Snapdragon Chemistry, a Cambrex company, has developed a new liquid-phase peptide synthesis (LPPS) technology utilizing active pharmaceutical ingredient (API) batch reactors and continuous flow.
Lonza inaugurated its new facility at the Colmar, France site. The new Innovaform Accelerator will serve as a Center of Excellence for developing and innovating capsule-based manufacturing and delivery solutions for oral and pulmonary administration.
Olon continues its growth path and increases its total production capacity following the acquisition of Huvepharma Italia and its site in Garessio, Cuneo, in the northwestern part of Italy.
Pfizer has commissioned its expanded, highly automated active pharmaceutical ingredient (API) manufacturing facility at the Tuas Biomedical Park in Singapore.
US contract development and manufacturing organization (CDMO) Veranova has initiated an expansion of its antibody-drug conjugate (ADC) and highly potent active pharmaceutical ingredient (HPAPI) development and manufacturing capabilities at its US facility in Devens, Massachusetts.
Siegfried, a global Contract Development and Manufacturing Organization (CDMO) for the pharmaceutical industry headquartered in Zofingen, Switzerland, has signed binding agreements with Curia Global for the acquisition of an early-phase CDMO site in Grafton, Wisconsin, US.
UK-headquartered contract development and manufacturing organization (CDMO) Sterling Pharma Solutions has invested $3 million at its US facility in Germantown, WI, to expand the company’s integrated antibody-drug conjugate (ADC) development and manufacturing capabilities.
Eli Lilly plans to invest another $5.3 billion in its US manufacturing site Lebanon, Indiana, increasing the company's total investment in this site $9 billion. The investment will expand Lilly's capacity to manufacture active pharmaceutical ingredients (API) for tirzepatide injections marketed under the Zepbound and Mounjaro brands.
The European Chemical Industry Council (CEFIC), through its subgroup European Fine Chemicals Group (EFCG), joined the Critical Medicines Alliance, an initiative of the European Commission to strengthen the supply of critical medicines in Europe.
Sandoz, a generic and biosimilar medicines manufacturer, recently opened a new production facility in Kundl, Austria, to serve more patients with affordable life-saving drugs produced entirely in Europe.
An innovative manufacturing platform called integrated continuous manufacturing (ICM) represents a completely modernized model for drug manufacturing. In contrast to batch processes, ICM’s unique operational advantages will allow for cost-competitive end-to-end manufacturing and enable a more robust and responsive supply chain for critical drugs.
Headquartered in Cramlington, UK, Sterling Pharma Solutions is a contract development and manufacturing organization (CDMO) that provides a range of services to the global biopharmaceutical industry, including active pharmaceutical ingredient (API) development, scale-up and cGMP manufacturing, as well as antibody drug conjugate (ADC) R&D and clinical-scale GMP manufacturing.
EuroAPI today announces that its Italian subsidiary, EuroAPI Italy S.R.L., is suspending the production of all APIs (active pharmaceutical ingredients) in Brindisi.
US biotech company Antheia and Olon, an Italian producer of active pharmaceutical ingredients (APIs), have announced the continuation of their ongoing partnership to utilize Olon’s fermentation infrastructure for the scale-up and commercialization of Antheia’s early products.
The pharmaceutical industry is a truly global and complex network of ingredients and materials suppliers, manufacturers, distributors for a variety of products ranging from vaccines to antibiotics and to therapeutic drugs for customers/patients.
Israeli generics manufacturer Teva Pharmaceuticals intends to divest its active pharmaceutical ingredient (API) business, Teva API (TAPI). A standalone business unit of Teva, TAPI supplies APIs to over 1,000 customers worldwide and has approximately 4,300 employees worldwide.
Olon Group is building a state-of-the-art High Potency Active Pharmaceutical Ingredient (HPAPI) suite at its Olon USA site in Concord, Ohio. This expands the company's capabilities for handling HPAPI, with investments totaling around €40 million ($43 million) in recent years.
Active pharmaceutical ingredients manufacturer EuroAPI has started a collaboration with Basel, Switzerland-headquartered SpiroChem, a contract research organization (CRO) which specializes in early chemical process R&D (route scouting).
US API maker Veranova has appointed Lucas Sauer-Jones as the company’s vice president & general manager, New England. He will be responsible for Veranova’s sites in Devens and North Andover.
Danish drugmaker Novo Nordisk plans to invest more than 42 billion Danish kroner (about €5.6 billion) starting in 2023 to expand existing manufacturing facilities at the company’s Kalundborg, Denmark, site to meet future market demands.
Olon, an Italian CDMO and API producer of active pharmaceutical ingredients (APIs), plans to invest €10 million in a multi-year expansion of its production site in Mahad, India.
Noramco, a US producer of active pharmaceutical ingredients (APIs), has completed the acquisition of the Cambrex drug product business unit previously known as Halo Pharmaceuticals. Financial details were not disclosed.
EuroAPI's Board of Directors decided that Karl Rotthier would step down as CEO, effective October 30, 2023. They initiated the search for a new CEO and appointed Viviane Monges, the current Board Chair, as interim CEO until a permanent successor is found, while she continues her role as Board Chair.
Farmabios, a company of the Axplora group founded in 2022, has received the cGMP approval from AIFA (national public body regulating medicines for human use in Italy) for the first line of its new production unit at Gropello Cairoli, Italy, expanding its large scale manufacturing capabilities for high potent active pharmaceutical ingredients (HPAPIs) and steroids.
Contract development and manufacturing organization (CDMO) AmbioPharm has appointed industry veteran Brian Gregg as CEO. Gregg, who has more than 30 years of experience in the peptide CDMO industry, succeeds Tim Nieters, who will be stepping down after seven years with the company.
Indian drugmaker Glenmark Pharma has agreed to sell 75% of the shares in its subsidiary Glenmark Life Sciences (GLS) to detergent manufacturer Nirma for 56.515 million Indian rupees (about €639.000).
Olon, an Italian CDMO and API producer, is investing a total of €100 million in 2023 to increase production capacity, in particular at its site in Mulazzano, Lodi province.
German chemical group Wacker has acquired 100% of ADL Biopharma from private equity investor Kartesia for a price said to exceed €100 million. It now owns the entire 150,000 m2 production site in the northern Spanish city of Léon with fermentation capacity of just under 3,000 cbm (gross volume).
Rotterdam-based speciality chemicals distributor IMCD kicked off the month of May agreeing a major distribution partnership and two outright acquisitions.
India-headquartered drugmaker Glenmark is said to be taking another look at selling a majority stake in its business with active pharmaceutical ingredients (APIs), which is wrapped up in subsidiary Glenmark Life Sciences.
Clear incentive for drug manufacturers to equip their production facilities with the capacity to process highly potent active pharmaceutical ingredients (HPAPIs). HPAPIs now account for 25% of all drugs produced globally, with some analysts projecting that it will reach a value of $40 billion by 2027.
Under US president Joe Biden, the Department of Justice has been moving energetically of late to uncover and prosecute offenses that might otherwise have been swept under heavy rugs, including Covid-related API manufacturing contracts won under unclear circumstances.
Macfarlan Smith, a UK-based unit of US API maker Veranova, formerly known as Johnson Matthey Health, has completed a $10 million expansion of its mid-scale active pharmaceutical ingredient (API) manufacturing capabilities in Edinburgh, Scotland.
Given the challenges the pharmaceutical industry is facing – secure material supply, reduce operation cost and increase flexibility, enhance sustainability and safety, innovate and reduce time-to-market – the sector is poised for a breakthrough of flow chemistry.
US CDMO Cambrex has agreed to buy Snapdragon Chemistry, a compatriot company specializing in developing continuous flow and batch processes for APIs. Snapdragon is based in Waltham, Massachusetts, where it employs 74 people.
Sandoz, the generics arm of Swiss drugmaker Novartis, has announced plans to spend an additional €50 million on raising European manufacturing capacity for finished dosage forms of amoxicillin and other key penicillin products.
Lonza has completed of the expansion of its Highly Potent API (HPAPI) multipurpose suite at the Basel-based CDMO’s alpine production site in Visp, Switzerland, adding development and manufacturing capacity for ADC payloads.
Financed in part by the French government’s France Relance plan, Novasep‐PharmaZell is investing €7.3 million in production of active pharmaceuticals (APIs) at its Mourenx, France, site.
WuXi AppTec and its subsidiary Wuxi STA have announced several investments in manufacturing and research in Asia, with the Changzou campus in China’s Jiangsu Province a focal point.
The Life Science business segment of German pharmaceuticals, chemicals and life sciences group Merck has widened its US plant for high-potent active pharmaceutical ingredients (HPAPIs) at Verona, near Madison, Wisconsin to 6,500 m2.
South Korean CDMO SK Pharmteco (SKTP) said it will spend $35 million on the initial phase of a planned expansion at the Dublin, Ireland, API site the conglomerate acquired from Bristol Myers Squibb in 2017. Prior to that, SK had been a BMS supplier for around a decade.
Major API supplier Olon is establishing a €10 million central R&D hub at its headquarters site in Roadano, near Milan. The Italian company said the facility paves the way for a further major expansion and diversification of its expertise in active pharmaceutical ingredients supplied to the CDMO and generics markets.
Centrient Pharmaceuticals has started its expanded production of statins at its manufacturing plant for active pharmaceutical ingredients (APIs) in Toansa, India. With the start-up of its second unit at the site, the Dutch company said it has doubled capacity for Atorvastatin and Rosuvastatin, meeting the increased demand for its sustainably produced portfolio.
US-based CDMO Regis Technologies has completed a major expansion of its laboratory facilities for development of active pharmaceutical ingredients (APIs) at its site in Morton Grove, Illinois. The project, kicked off two years ago, doubles the company’s capacity to take on new development projects.
Cambrex is spending $3.6 million to expand flexible drug substance manufacturing at its site in Karlskoga, Sweden. Engineering has already begun, and work is expected to be completed by November 2020.
With this acquisition, Olon said it has successfully finalized its three-year development plan and will now move to its next target, which is to play an important role in manufacturing biologics APIs.
Lugano, Switzerland-based chemical and biological API manufacturer Cerbios announced that its board of directors has approved the installation of a new production line in its building dedicated for high potency active ingredients (HPAIs).
Saltigo, the custom manufacturing business of Lanxess' Advanced Intermediates segment, which achieved total sales of €1.5 billion in 2011, has realigned its strategy.
